209 related articles for article (PubMed ID: 34494300)
21. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
[TBL] [Abstract][Full Text] [Related]
22. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
[TBL] [Abstract][Full Text] [Related]
23. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
24. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin.
Cánovas A; Alonso JJ; Barreiro G; Aguirre C
Tumori; 2010; 96(1):117-21. PubMed ID: 20437868
[TBL] [Abstract][Full Text] [Related]
26. Predictive value of prognostic indices in patients with follicular lymphomas.
Radojkovic M; Ristic S; Colovic M; Mihaljevic B; Cemerikic-Martinovic V
Med Oncol; 2006; 23(4):533-42. PubMed ID: 17303912
[TBL] [Abstract][Full Text] [Related]
27. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma.
Giné E; Montoto S; Bosch F; Arenillas L; Mercadal S; Villamor N; Martínez A; Colomo L; Campo E; Montserrat E; López-Guillermo A
Ann Oncol; 2006 Oct; 17(10):1539-45. PubMed ID: 16940035
[TBL] [Abstract][Full Text] [Related]
28. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
[TBL] [Abstract][Full Text] [Related]
29. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
[TBL] [Abstract][Full Text] [Related]
30. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
Găman AM
Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression.
Montoto S; López-Guillermo A; Altés A; Perea G; Ferrer A; Camós M; Villela L; Bosch F; Esteve J; Cervantes F; Bladé J; Nomdedeu B; Campo E; Sierra J; Montserrat E
Ann Oncol; 2004 Oct; 15(10):1484-9. PubMed ID: 15367408
[TBL] [Abstract][Full Text] [Related]
32. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors JM; Gascoyne RD; Hiddemann W; Unterhalt M; Weinstock DM; Weigert O
Blood; 2016 Aug; 128(8):1112-20. PubMed ID: 27418643
[TBL] [Abstract][Full Text] [Related]
33. Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.
Sarkozy C; Trneny M; Xerri L; Wickham N; Feugier P; Leppa S; Brice P; Soubeyran P; Gomes Da Silva M; Mounier C; Offner F; Dupuis J; Caballero D; Canioni D; Paula M; Delarue R; Zachee P; Seymour J; Salles G; Tilly H
J Clin Oncol; 2016 Aug; 34(22):2575-82. PubMed ID: 27298402
[TBL] [Abstract][Full Text] [Related]
34. External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse.
Boyne DJ; Chua N; Owen C; Joe-Uzuegbu O; Shakir H; Gogna P; Jarada TN; Brenner DR; Elia-Pacitti J; Ewara EM; Cheung WY
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e277-e285. PubMed ID: 37331847
[TBL] [Abstract][Full Text] [Related]
35. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.
Méndez M; Torrente M; Sánchez-Beato M; González-Rincón J; Royuela A; Gómez-Codina J; de la Cruz-Merino L; Rueda A; Llanos M; Quero C; Rodríguez-Abreu D; Gumá J; Monsalvo S; Sabin P; Provencio M
Hematol Oncol; 2019 Apr; 37(2):143-150. PubMed ID: 30840776
[TBL] [Abstract][Full Text] [Related]
36. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D
Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients.
Heilgeist A; McClanahan F; Ho AD; Witzens-Harig M
Cancer; 2013 Jan; 119(1):99-106. PubMed ID: 22736411
[TBL] [Abstract][Full Text] [Related]
38. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.
Freeman CL; Kridel R; Moccia AA; Savage KJ; Villa DR; Scott DW; Gerrie AS; Ferguson D; Cafferty F; Slack GW; Farinha P; Skinnider B; Connors JM; Sehn LH
Blood; 2019 Aug; 134(9):761-764. PubMed ID: 31300404
[TBL] [Abstract][Full Text] [Related]
39. Low T3 syndrome as a predictor of poor outcomes in patients with follicular lymphoma.
Xue LG; Shen HR; Gao R; Du KX; Xing TY; Wang WT; Wang L; Li JY; Liang JH; Xu W
Ann Hematol; 2023 Apr; 102(4):851-862. PubMed ID: 36735075
[TBL] [Abstract][Full Text] [Related]
40. Rituximab in the therapy of stage III and IV follicular lymphoma: Results of the REFLECT 1 study of the Serbian Lymphoma Group.
Popovic S; Jovanovic D; Mihaljevic B; Andjelkovic N; Marjanovic G; Marisavljevic D; Vlaisavljevic N; Popovic L; Salma S; Agic D; Milosevic R; Smiljanic M; Sretenović S; Djurdjević P; Markovic O; Hajder J; Govedarovic N
J BUON; 2017; 22(2):487-494. PubMed ID: 28534374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
